The benefits of validation of methods for toxicity testing outweigh its costs

Main Article Content

Anne Gourmelon , Philippe Hubert, Elise Grignard, Lisa Baumann, Sharon Munn, Cécile Michel-Caillet
[show affiliations]

Abstract

The 4th Annual Forum on Endocrine Disrupters organized by the European Commission brought together the authors of this article around the topic: “From bench to validated test guidelines: (pre)val­idation of test methods”. Validation activities are meant to demonstrate the relevance and reliability of methods and approaches used in regulatory safety testing. These activities are essential to facil­itate regulatory use, still they are largely underfunded and unattractive to the scientific community. In the last decade, large amounts of funding have been invested in European research towards the development of approaches that can be used in regulatory decision-making, including for the identification of endocrine disrupters. There is a vast pool of candidate test methods for potential reg­ulatory applications, but most of them will not be used due to the absence of consideration of their relevance and reliability outside the method developer’s laboratory. This article explains the reasons why such a gap exists between the outputs of research projects and the uptake in a regulatory context. In parallel, there are also increasing expectations from the regulatory science community that validation becomes more efficient with respect to time and resources. This article shares some of the lessons learned and proposes paths forward for validation of new methods that are not intended as one-to-one replacements of animal studies. This includes submitting only mature methods for validation that were developed following good practices and good documentation, proposing a greater emphasis on well-documented transferability studies, and adopting a cost-sharing model among those who benefit from validated methods.


Plain language summary
Validation activities for methods intended to be used to assess chemical safety have a cost but also bring substantial benefits when the validated methods are established as OECD Test Guidelines, which results in mutual acceptance of data generated by the methods across OECD member and adhering countries. The article discusses some of the challenges faced when method validation is underfunded and unattractive for researchers. Proposals are made to improve the current situation, gain efficiency, and make validation a shared responsibility.

Article Details

How to Cite
Gourmelon, A. . (2024) “The benefits of validation of methods for toxicity testing outweigh its costs”, ALTEX - Alternatives to animal experimentation, 41(3), pp. 395–401. doi: 10.14573/altex.2403051.
Section
Articles
Author Biography

Sharon Munn, European Commission, Joint Research Centre (JRC), Ispra, Italy

European Commission, Joint Research Centre (JRC), Ispra, Italy

References

Baker, M. (2016). 1,500 scientists lift the lid on reproducibility. Nature 533, 452-454. doi:10.1038/533452a

Burgdorf, T., Piersma, A. H., Landsiedel, R. et al. (2019). Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology – Evolution versus revolution. Toxicol In Vitro 59, 1-11. doi:10.1016/j.tiv.2019.03.039

Crouzet, T., Grignard, E., Brion, F. et al. (2023). ReadEDTest: A tool to assess the readiness of in vitro test methods under development for identifying endocrine disrupters. Environ Int 174, 107910. doi:10.1016/j.envint.2023.107910

EU (2022). Report of the 4th Annual Forum on Endocrine Disrupters. Exchanging knowledge, identifying challenges, building synergies, 21-22 September 2022. Luxembourg: Publications Office of the European Union. doi:10.2779/71861

Holbech, H., Matthiessen, P., Hansen, M. et al. (2020) ERGO: Breaking down the wall between human health and environmental testing of endocrine disrupters. Int J Mol Sci 21, 2954. doi:10.3390/ijms21082954

OECD (2005). Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment. OECD Series on Testing and Assessment, No. 34. OECD, Paris. https://one.oecd.org/document/env/jm/mono(2005)14/en/pdf

OECD (2016). Guidance Document on the reporting of defined approaches to be used in integrated approaches to testing and assessment. OECD Series on Testing and Assessment, No. 255. OECD, Paris. https://one.oecd.org/document/env/jm/mono(2016)28/en/pdf

OECD (2018). Guidance Document on Good In Vitro Method Practice. OECD Series on Testing and Assessment, No. 286. OECD, Paris. doi:10.1787/9789264304796-en.

OECD (2019a). Guiding Principles on Good Practices for the Availability/Distribution of Protected Elements in OECD Test Guidelines. OECD Series on Testing and Assessment, No. 298. OECD, Paris. https://one.oecd.org/document/env/jm/mono(2019)14/en/pdf

OECD (2019b). Saving Costs in Chemicals Management: How the OECD Ensures Benefits to Society https://www.oecd.org/chemicalsafety/saving-costs-in-chemicals-management-9789264311718-en.htm

OECD (2023). Report on the WNT Workshop how to prepare the Test Guidelines Programme for emerging technologies. OECD Series on Testing and Assessment, No. 378. OECD, Paris. https://one.oecd.org/document/ENV/CBC/MONO(2023)14/en/pdf

Piersma, A. H., Burgdorf, T., Louekari, K. et al. (2018). Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies. Toxicol In Vitro 50, 62-74. doi:10.1016/j.tiv.2018.02.018

van der Zalm, A. J., Barroso, J., Browne, P. et al. (2022). A framework for establishing scientific confidence in new approach methodologies. Arch Toxicol 96, 2865-2879. doi:10.1007/s00204-022-03365-4

Most read articles by the same author(s)